Solid State Stability of Extemporaneously Prepared Levothyroxine Aliquots and Capsules
Author(s): Fortner Jeff, Salton Jason, Carlson Christie, Wheeler Rich, Cote Brianna, Rao Deepa
Issue: Sep/Oct 2015 - Volume 19, Number 5
View All Articles in Issue
Page(s): 414-419
Download in electronic PDF format for $75
Abstract: The purpose of this research was to collect, analyze, and compare stability data for levothyroxine (T4) powder in the anhydrous and pentahydrate form when prepared as an aliquot and in capsules. Two different compounding pharmacies, Central Iowa Compounding and Gateway Medical Pharmacy, used different forms of T4 and aliquot formulations, which were studied to determine the beyond-use date at ±5% or ±10% of labeled strength. T4 was extracted from aliquot and capsule formulations and assessed using reverse-phase highperformance liquid chromatography validated to differentiate between the degraded and original forms of T4. The results indicate that T4 1:100 aliquot formulation prepared with silica gel or Avicel as filler are stable for 120 days at ±10% labeled potency, but at ±5% labeled potency, the silica gel and Avicel aliquot formulations are stable for 45 and 30 days, respectively. The silica gel capsules prepared from fresh aliquot were stable for 120 days at ±10% labeled potency and 90 days at ±5% labeled potency, while the Avicel capsules prepared from fresh aliquot were stable for 180 days at both ±10% and ±5% labeled potency. Avicel capsules prepared from old aliquot (120 days) and fresh aliquot (1 day) were also compared for stability. The old aliquot Avicel capsules were stable for 14 days at ±5% labeled potency and 150 days at ±10% labeled potency, while new aliquot Avicel capsules were stable for 180 days at both ±10% and ±5% labeled potency. Based on our data, there can be significant variation in the beyond-use dates assigned to T4 capsules based on the diluents used for aliquots, the final capsule formulations, and the potency standards applied. These results also indicate that pharmacists must exercise caution when using older aliquots and may have to assign shorter beyond-use dates.
Related Keywords:
levothyroxine, hypothyroidism, thyroid T4 replacement hormone, anhydrous, pentahydrate, aliquots, capsules, stability, potency standards, storage temperature
Related Categories:
EXCIPIENTS, FORMULATIONS, PEER-REVIEWED, STABILITIES, COMPATIBILITIES, DOSAGE FORMS/DRUG CARRIERS, ENDOCRINOLOGY/HORMONES/ MENOPAUSE/ANDROPAUSE
Printer-Friendly Version
Related Articles from IJPC |
Title/Author
(Click for Abstract / Details / Purchase) |
Issue/Page
View/Buy |
Solid State Stability of Extemporaneously Prepared Levothyroxine Aliquots and Capsules
Fortner Jeff, Salton Jason, Carlson Christie, Wheeler Rich, Cote Brianna, Rao Deepa
|
Sep/Oct 2015
Pg. 414-419
|
Stability of Levothyroxine, Doxycycline, Hydrocortisone, and Pravastatin in Liquid Dosage Forms Stored at Two Temperatures
Nahata Milap C
|
Sep/Oct 2015
Pg. 428-431
|
Levothyroxine Sodium 100-mcg Capsules
Allen Loyd V Jr
|
Nov/Dec 2013
Pg. 505
|
Hypothyroidism: Optimizing Therapy with Slow-Release Compounded Thyroid Replacement
Milner Martin
|
Jul/Aug 2005
Pg. 268-273
|
Bioidentical Thyroid Replacement Therapy in Practice: Delivering a Physiologic T4-T3 Ratio for Improved Patient Outcomes with the Listecki-Snyder Protocol
Snyder Scott, Listecki Robert E
|
Sep/Oct 2012
Pg. 376-380
|
Influence of Temperature on the Thirty-Day Chemical Stability of Extemporaneously Prepared Dexamethasone Paste
Dudley Richard, McDowell Brean, Mahl Carissa, Sarkar Arindam Basu
|
May/Jun 2012
Pg. 258-261
|
Thyroid Potency Calculations
Stack Bob
|
Jul/Aug 2010
Pg. 306-309
|
The Basics of Compounding: Compounding Special Capsules
Allen Loyd V Jr
|
Jul/Aug 1999
Pg. 291-294
|
Formulation and Stability Evaluation of Extemporaneously Prepared Atenolol Capsules from Crushed Atenolol Tablets
Zaid Abdel Naser, Malkieh Numan, Kharoaf Maher, Ghoush Abeer Abu, Al-Ramahi Rowa'
|
Jul/Aug 2012
Pg. 342-346
|
Stability of an Extemporaneously Formulated Levothyroxine Sodium Syrup Compounded from Commercial Tablets
Alexander Kenneth S, Kothapalli Madhu R, Dollimor David
|
Jan/Feb 1997
Pg. 60-63
|
Levothyroxine Sodium 40-micro-g/mL Oral Liquid
Allen Loyd V Jr
|
May/Jun 2007
Pg. 247
|
Stability of 4-Aminopyridine and 3,4-Diaminopyridine Oral Capsules
Trissel Lawrence A, Xu Quanyun A, Zhang Yanping
|
Mar/Apr 2002
Pg. 155-157
|
The Influence of Tablet Formulation, Drug Concentration, and pH Modification on the Stability of Extemporaneously Compounded Levothyroxine Suspensions
Svirskis Darren, Lin Shao-Wei, Brown Helen, Sangaroomthong Annie, Shin Daniel, Wang Ziqi, Xu Hongtao, Dean Rebecca, Vareed Preetika, Jensen Maree, Wu Zimei
|
Mar/Apr 2018
Pg. 164-171
|
Mean Kinetic Temperature for Controlled Room Temperature Drug Storage: Official Definitions and Example Calculations
Newton David W
|
Jul/Aug 2019
Pg. 281-287
|
Stability of Extemporaneously Prepared Hydroxychloroquine Sulfate 25-mg/mL Suspensions in Plastic Bottles and Syringes
McHenry Adam R, Wempe Michael F, Rice Peter J
|
May/Jun 2017
Pg. 251-254
|
Stability of Fagron's Phytobase Cream Compounded with Various Hormones
Wynn Tom, Taylor Sarah, Zander Clark
|
Mar/Apr 2021
Pg. 156-162
|
Differentiation and Treatment of Hypothyroidism, Functional Hypothyroidism, and Functional Metabolism
Paoletti Jim
|
Nov/Dec 2008
Pg. 488-497
|
Differentiation and Treatment of Hypothyroidism, Functional Hypothyroidism, and Functional Metabolism
Paoletti Jim
|
Jan/Feb 2024
Pg. 34-43
|
Using Serum Hormone Analysis to Develop Hormone Replacement Therapy Regimens - Part 2
Ford Gina, Garcia Lea
|
Jan/Feb 2001
Pg. 52-54
|
Stability Issues for Compounding Extemporaneously Prepared Oral Formulations for Pediatric Patients
Schotik Debora
|
Jan/Feb 2001
Pg. 9-12
|
Return to Top |